Clinical Study
Safety of a New Chewable Formulation of Mebendazole for Preventive Chemotherapy Interventions to Treat Young Children in Countries with Moderate-to-High Prevalence of Soil Transmitted Helminth Infections
Table 3
TEAEs observed in at least 1% of the patient population.
| ||||||||||||||||||||||||||||||||||||||||||||
TEAE: treatment-emergent adverse event. |